Its interchangeable aptamers pose a way to effectively target a wide variety of NSCLC mutations and regulation of the PD-1/PD-L1 axis may increase the efficacy of PD-1 inhibitor drugs. Here, CD274 is linked to non-small cell lung carcinoma.